Back To: Home : Featured Technology : Flow Cytometry

CLICK HERE FOR WHAT'S NEW IN:
 

One last deal for 2019
January 2020
SHARING OPTIONS:

ST. LOUIS—In December, Canopy Biosciences LLC has acquired Core Diagnostics, a provider of biomarker analysis services for biopharmaceutical researchers, in a transaction that will enable Canopy to offer its multi-omic immune profiling services in the CLIA environment. Canopy also acquired  Zellkraftwerk GmbH earlier in 2019.
 
“By combining multi-omic technologies such as Chip Cytometry, NanoString and RareSeq, we are building a unique and powerful platform for immune profiling of cells and tissues. Through the addition of Core Diagnostics, this innovative multi-omics platform will now be available to customers in the clinical space, in addition to the preclinical and translational customers we already work with,” said Dr. Edward Weinstein, president and CEO of Canopy.

Back


PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.